Contact us
Close

Getting in touch

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean condimentum justo massa, ut dapibus nisl vestibulum ac. Vestibulum dapibus dui ac tortor gravida pellentesque. Nam ut velit non sapien vulputate volutpat in pretium dui. Mauris malesuada urna et metus dignissim, cursus tincidunt.

Clinical trials

A ‘clinical trial’ is a research study in which people agree to test a potential new treatment to prevent or improve a disease or medical condition. A clinical trial also looks at how participants react to the potential new treatment and if any unwanted effects occur. This helps to determine if the new investigational treatment works, is safe, and is better than those that are already available. Many clinical trials also compare existing treatments or test new ways to use or combine existing treatments.

A.

Clinical trial of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck

Debiopharm International is conducting a pre-operative, open-label Definition An open-label trial means that no placebo is administered and that patients know what treatment they are given. , non-randomized “window-of-opportunity” trial in male and female patients with resectable squamous cell cancer of the head and neck (oral cavity, oropharynx, hypopharynx and larynx). A “window-of-opportunity” trial is a trial in which patients receive one or more new compounds between their cancer diagnosis and standard treatment (mainly surgery) to obtain knowledge about the anti-tumor activity of the new agent in a disease state that is not disturbed by previous or simultaneous treatments.

The purpose of this trial is to evaluate the effects of Debio 1143 Definition Debio 1143 is a small molecule that neutralizes inhibitor of proteins that induce the cell death by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC).Debio 1143 aims to improve cancer patient treatment outcomes by sensitizing cancer cells to the action of chemotherapy, radiotherapy, and/or immune checkpoint inhibitors. Debio 1143 is a potent orally available IAP inhibitor currently in development in Head and Neck, Ovarian and advanced solid tumors. For more info: http://bit.ly/2xa7RUK administered alone or combined with cisplatin Definition the standard therapy for this type of cancer or cisplatin Definition the standard therapy for this type of cancer alone in the above disease in a pre-operative setting. Debio 1143 Definition Debio 1143 is a small molecule that neutralizes inhibitor of proteins that induce the cell death by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC).Debio 1143 aims to improve cancer patient treatment outcomes by sensitizing cancer cells to the action of chemotherapy, radiotherapy, and/or immune checkpoint inhibitors. Debio 1143 is a potent orally available IAP inhibitor currently in development in Head and Neck, Ovarian and advanced solid tumors. For more info: http://bit.ly/2xa7RUK is an investigational medicinal product. Cisplatin is a drug approved for the treatment of this disease.

A first group patients has already been treated with Debio 1143 Definition Debio 1143 is a small molecule that neutralizes inhibitor of proteins that induce the cell death by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC).Debio 1143 aims to improve cancer patient treatment outcomes by sensitizing cancer cells to the action of chemotherapy, radiotherapy, and/or immune checkpoint inhibitors. Debio 1143 is a potent orally available IAP inhibitor currently in development in Head and Neck, Ovarian and advanced solid tumors. For more info: http://bit.ly/2xa7RUK alone. A second group of patients will be treated shortly with Debio 1143 Definition Debio 1143 is a small molecule that neutralizes inhibitor of proteins that induce the cell death by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC).Debio 1143 aims to improve cancer patient treatment outcomes by sensitizing cancer cells to the action of chemotherapy, radiotherapy, and/or immune checkpoint inhibitors. Debio 1143 is a potent orally available IAP inhibitor currently in development in Head and Neck, Ovarian and advanced solid tumors. For more info: http://bit.ly/2xa7RUK combined with cisplatin Definition the standard therapy for this type of cancer or cisplatin Definition the standard therapy for this type of cancer alone until surgery. Debio 1143 Definition Debio 1143 is a small molecule that neutralizes inhibitor of proteins that induce the cell death by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC).Debio 1143 aims to improve cancer patient treatment outcomes by sensitizing cancer cells to the action of chemotherapy, radiotherapy, and/or immune checkpoint inhibitors. Debio 1143 is a potent orally available IAP inhibitor currently in development in Head and Neck, Ovarian and advanced solid tumors. For more info: http://bit.ly/2xa7RUK is administered orally once daily for 15 days prior to surgery. Cisplatin is administered by infusion on once weekly over 15 days.

  • _Phases

    • P
    • M

Back to the pathologies